Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cance... (

HOME >> BIOLOGY >> TECHNOLOGY

Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients

Date:2/25/2009

- MDV3100 Consistently Demonstrates Anti-Tumor Activity Across Doses and Endpoints in both Chemotherapy Naive and Post-Chemotherapy Patients -

- Data To Be Presented at ASCO's 2009 Genitourinary Cancers Symposium -

- Medivation to Host Conference Call and Webcast Presentation with Dr. Howard Scher Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new efficacy and safety data from an ongoing Phase 1-2 clinical trial of the Company's novel androgen receptor antagonist MDV3100 in castration-resistant prostate cancer (CRPC) patients. The new efficacy data cover all 114 patients who have been followed for 12 weeks or longer, and show that MDV3100 consistently demonstrated encouraging anti-tumor activity across dose levels and endpoints.

"The data thus far suggest a favorable benefit/risk ratio for MDV3100 in treating castration-resistant prostate cancer patients," said Howard Scher, M.D., principal investigator of the trial and chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center. "These men have a limited life expectancy, and currently their only approved treatment option is chemotherapy. Given these encouraging results and the large unmet medical need for men with castration-resistant prostate cancer, I am enthusiastic about working with Medivation to advance MDV3100 into Phase 3 clinical development this year."

All patients had progressive disease upon enrollment and were heavily pretreated, with 77 percent having failed at least two lines of prior hormonal therapy and 43 percent having also failed one or more chemotherapy regimens. Efficacy endpoints in the study included circulating tumor
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Medivation Presents New Data on Dimebons Novel Mechanism of Action
2. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
5. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
6. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
8. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008

Post Your Comments:

(Date:6/18/2013)... Clara, CA (PRWEB) June 18, 2013 ... to standard size SEMs but have limited performance and ... lower resolution. Full size SEMs would normally provide better ... more knowledge to operate and have a higher cost ... address the gap between these two types of ...

(Date:6/18/2013)... 2013) A million electric cars could be on roads ... the help of research by the United States Department of ... , Professor Zhongwei Chen is part of a team led ... materials to replace the expensive platinum catalysts in fuel cells. ... fuel cells in vehicles is the cost of the units. ...

(Date:6/18/2013)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing, and stem ... results for the fourth quarter and full year of ... Fourth Quarter of Fiscal 2013 Highlights , ... by 33.3% to RMB133.0 million ($21.4 million) from RMB99.8 ...

(Date:6/18/2013)... June 18, 2013 In support of ... the Consulate General of Switzerland in New York is ... Switzerland’s MS Tûranor PlanetSolar , to Manhattan. PlanetSolar ... DeepWater Expedition 2013 tour with scientists on board from ... Gérard d’Aboville, runs exclusively on energy from the sun ...

[0] Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes [0] US and Canadian researchers drive towards cheaper fuel cells for electric cars [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City

... ... world, FAIRFAX, Va., Jan. 8 As ... ) today,announced the appointment of Timothy J. Atkin as Senior Vice President and,Mike ... Sector (GHS) organization. GHS was formed in October 2007 to,expand SRA,s footprint in ...

... HUBBARD, Ohio, Jan. 8 NanoLogix, Inc. (OTC:,NNLX), ... the company,has been named "Stock Pick of January ... vice president, stated,that "This is another example of ... We are happy to be selected by Stockprowler,-- ...

... and,momentum behind its research-and-development (R&D) pipeline has Monsanto,(NYSE: ... to farmers,by 2012, company leaders will tell investors today. ... presentations on the company,s R&D pipeline in New,York and ... the pipeline right now," said,Steve Padgette, vice president of ...

Cached Biology Technology:SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 2 SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer 3 NanoLogix, Inc. Makes Stock Pick List 2 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 2 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 3

SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer NanoLogix, Inc. Makes Stock Pick List Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade

(Date:6/18/2013)... Joshua Obar, Ph.D., Department of Immunology and Infectious ... 2013 ICAAC Young Investigator Award for his research on ... to infection. , Obar earned his B.A. in ... on to complete his Ph.D. in Microbiology and Immunology ... Ph.D. thesis research in Edward Usherwood,s laboratory at the ...

(Date:6/18/2013)... The herbal extract of a yellow-flowered mountain plant long ... lifespan of fruit fly populations by an average of ... it,s how Rhodiola rosea , also ... attention of study leaders Mahtab Jafari and Sam Schriner. ... manner completely unrelated to dietary restriction and affects different ...

(Date:6/18/2013)... a chemical modification of DNA and this modification ... DNA sequence. Until now, scientists believed that this ... genes. Today, a team of researchers from the ... Dermitzakis, Louis-Jeantet Professor at the Faculty of Medicine, ... and that DNA methylation may play both a ...

Breaking Biology News(10 mins):The American Society for Microbiology honors Joshua Obar 2 Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2 The secret of DNA methylation 2

[0] The American Society for Microbiology honors Joshua Obar [0] Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds [0] The secret of DNA methylation

... Nanotechnology (IBN) have succeeded in unlocking the potential of ... converting it into a more useful product. ... the IBN researchers report that by using organocatalysts, they ... to produce methanol, a widely used industrial feedstock and ...

... blood supply to the brain is restricted. Initially, brain ... activates harmful inflammatory processes in the affected area of ... Neurology Clinic at Heidelberg University Hospital have shown that ... a stroke. These cells are known as regulatory T ...

... RIVERSIDE, Calif. A researcher at UC Riverside has discovered a ... moss or a dry leaf and named it after President ... doing a survey for lichen diversity on Santa Rosa Island in ... Herbarium . "I named it Caloplaca obamae to show ...

Cached Biology News:Singapore researchers first to transform carbon dioxide into methanol 2 'First aid' for brain cells comes from blood 2 UC Riverside researcher names lichen after President Barack Obama 2

Singapore researchers first to transform carbon dioxide into methanol 'First aid' for brain cells comes from blood UC Riverside researcher names lichen after President Barack Obama

... Maximize the value of your microarray ... offer the support you need from ... the most up to date methods. ... the Gene Expression Profiling Service or ...

... number is a new product number, ... number. If showing no availability yet, ... number (Z71,517-4) or contact customer service ... (expanded surface, easy grip) ...

... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: ...

... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ...

Biology Products:

Illumina Standard Data Analysis Report from Asuragen, Inc.CORNING 1700CM2 ROLLER BOTTLE, EASY GRIP CAP, GRADUATED, STERILE from Sigma-Aldrich CORNING ROLLER BOTTLES, 490 CM2, PS CAP, PLUG SEAL, STERILE from Sigma-Aldrich CORNING ROLLER BOTTLE WITH CELLBIND, 1700CM2, STERILE from Sigma-Aldrich